
Novo Nordisk's European stock rose over 4%, with the company's fourth-quarter sales increasing by 6.3%, exceeding market expectations

Novo Nordisk's European stock rose over 4%, with the company's fourth-quarter sales increasing by 6.3%, exceeding market expectations. Risk warning and disclaimer: The market has risks, and investment requires caution. This article does not constitute personal investment advice and does not take into account the specific investment goals, financial conditions, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article align with their specific circumstances. Investment based on this is at one's own risk
Novo Nordisk's European stock rose over 4%, with the company's fourth-quarter sales increasing by 6.3%, exceeding market expectations.
Risk Warning and Disclaimer
The market carries risks, and investments should be made cautiously. This article does not constitute personal investment advice and does not take into account the specific investment objectives, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Investing based on this is at one's own risk